Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Accumulated Depreciation & Amortization (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Accumulated Depreciation & Amortization for 10 consecutive years, with $22.4 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $22.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $22.4 million, a N/A change, with the full-year FY2024 number at $22.4 million, changed N/A from a year prior.
  • Accumulated Depreciation & Amortization was $22.4 million for Q4 2024 at Theravance Biopharma, down from $32.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $45.8 million in Q4 2020 to a low of $22.4 million in Q4 2024.
  • A 3-year average of $33.7 million and a median of $32.8 million in 2022 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 3.7% in 2020; the steepest drop was 3.7% in 2020.
  • Theravance Biopharma's Accumulated Depreciation & Amortization stood at $45.8 million in 2020, then decreased by 28.32% to $32.8 million in 2022, then crashed by 31.78% to $22.4 million in 2024.
  • Per Business Quant, the three most recent readings for TBPH's Accumulated Depreciation & Amortization are $22.4 million (Q4 2024), $32.8 million (Q4 2022), and $45.8 million (Q4 2020).